On Friday, Perspective Therapeutics Inc (AMEX: CATX) was 4.84% up from the session before settling in for the closing price of $1.86. A 52-week range for CATX has been $1.60 – $19.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 1.39% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -2.78%. With a float of $53.81 million, this company’s outstanding shares have now reached $70.67 million.
In an organization with 140 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Perspective Therapeutics Inc (CATX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Perspective Therapeutics Inc stocks. The insider ownership of Perspective Therapeutics Inc is 27.34%, while institutional ownership is 68.22%. The most recent insider transaction that took place on Mar 28 ’25, was worth 49,384. In this transaction Chief Executive Officer of this company bought 22,026 shares at a rate of $2.24, taking the stock ownership to the 59,383 shares. Before that another transaction happened on Mar 28 ’25, when Company’s Chief Executive Officer bought 4,650 for $2.21, making the entire transaction worth $10,288. This insider now owns 4,650 shares in total.
Perspective Therapeutics Inc (CATX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.72% during the next five years compared to -9.86% drop over the previous five years of trading.
Perspective Therapeutics Inc (AMEX: CATX) Trading Performance Indicators
You can see what Perspective Therapeutics Inc (CATX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 99.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.44 in one year’s time.
Technical Analysis of Perspective Therapeutics Inc (CATX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was better than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 47.96%. Additionally, its Average True Range was 0.22.
During the past 100 days, Perspective Therapeutics Inc’s (CATX) raw stochastic average was set at 4.77%, which indicates a significant decrease from 38.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.74% in the past 14 days, which was lower than the 142.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.5966, while its 200-day Moving Average is $8.0003. However, in the short run, Perspective Therapeutics Inc’s stock first resistance to watch stands at $2.0500. Second resistance stands at $2.1500. The third major resistance level sits at $2.3000. If the price goes on to break the first support level at $1.8000, it is likely to go to the next support level at $1.6500. Assuming the price breaks the second support level, the third support level stands at $1.5500.
Perspective Therapeutics Inc (AMEX: CATX) Key Stats
There are 74,052K outstanding shares of the company, which has a market capitalization of 144.40 million. As of now, sales total 1,450 K while income totals -79,280 K. Its latest quarter income was 230 K while its last quarter net income were -40,170 K.
